TrialPath
Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960 · Blueprint Medicines Corporation
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
About this study
This is an open-label, multi-center, Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of BLU-924, a pan-KRAS inhibitor, in participants with metastatic KRAS mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC). The monotherapy part of the study includes Dose Escalation, Dose Enrichment, and Dose Expansion. Participants enrolled during Dose Escalation and Dose Enrichment will be evaluated for dose limiting toxicities (DLTs) to determine the MTD. Participants enrolled into disease-specific Enrichment cohorts will enable a more robust characterization of safety, PK, pharmacodynamics, and preliminary clinical activity. Enrolment into Dose Expansion will follow the identification of at least 1 recommended dose for expansion (RDFE) based on data from the Dose Escalation and Dose Enrichment. No combination arm is active at this time.
Eligibility criteria
Inclusion Criteria: 1. Pathologically confirmed diagnosis of metastatic Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA). 2. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. 4. Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapies due to clinical characteristics, comorbidities, or other medically justified reasons. Exclusion Criteria: 1. History of additional malignancy within the last 2 years, with some exceptions as specified in the protocol. 2. Active brain metastases (participants with asymptomatic brain metastases may be eligible). 3. Have received prior targeted treatment(s) against KRAS, including pan-KRAS inhibitors, multi-RAS inhibitors, mutant-selective KRAS inhibitors, and RAS or KRAS degraders. 4. Active or uncontrolled systemic infection, such as tuberculosis, Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study design
Enrollment target: 265 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-04
Estimated completion: 2031-07
Last updated: 2026-09-21
Interventions
Drug: BLU-924
Primary outcomes
  • • Dose Escalation and Enrichment: Percentage of Participants with Dose-limiting Toxicity (DLTs) (Up to 5 years)
  • • Dose Escalation, Enrichment and Expansion: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (Up to 5 years)
  • • Dose Escalation and Enrichment: Maximum Tolerated Dose (MTD) of BLU-924 (Up to 5 years)
Sponsor
Blueprint Medicines Corporation · industry
With: Sanofi
Contacts & investigators
ContactBlueprint Medicines · contact · medinfo@blueprintmedicines.com · 1-888-258-7768
All locations (16)
Florida Cancer Specialists & Research Institute - SarasotaRecruiting
Sarasota, Florida, United States
Moffitt Cancer CenterRecruiting
Tampa, Florida, United States
Mary Bird Perkins Cancer CenterNot Yet Recruiting
Baton Rouge, Louisiana, United States
Massachusetts General Hospital - Main CampusNot Yet Recruiting
Boston, Massachusetts, United States
University of Michigan Medical School Rogel Cancer CenterNot Yet Recruiting
Ann Arbor, Michigan, United States
Hackensack University Medical CenterNot Yet Recruiting
Hackensack, New Jersey, United States
NYU Langone Health Perlmutter Cancer CenterNot Yet Recruiting
New York, New York, United States
Tennessee Oncology, PLLCNot Yet Recruiting
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center - Texas Medical CenterNot Yet Recruiting
Houston, Texas, United States
Next Oncology Virginia Cancer SpecialistRecruiting
Fairfax, Virginia, United States
Mi Cancer Center Barcelona (Pratia Sirius Barcelona)Not Yet Recruiting
Barcelona, Catalonia, Spain
Hospital Universitario Vall d'HebronNot Yet Recruiting
Barcelona, Catalonia, Spain
Hospital General Universitrio Gregorio MaranonNot Yet Recruiting
Madrid, Madrid, Spain
Hospital Universitario 12 de OctubreNot Yet Recruiting
Madrid, Madrid, Spain
NEXT Oncology - MadridNot Yet Recruiting
Pozuelo de Alarcón, Madrid, Spain
Clinica Universidad de Navarra (CUN)Not Yet Recruiting
Pamplona, Navarre, Spain